Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
Data generated in the new National Cancer Institute drug evaluation program, which is based on inhibition of cell growth in 60 human tumor cell lines, were used to compare new compounds with agents of known mechanism of action in terms of their differential cytotoxicity. Two marine natural products, halichondrin B and homohalichondrin B, appeared repeatedly when the data base was probed with known antimitotic agents. We confirmed that both compounds were highly cytotoxic (IC50 values for L1210 murine leukemia cells of 0.3 and 1 nM, respectively), with accumulation of cells arrested in mitosis at toxic concentrations, that both inhibited the polymerization of purified tubulin, and that both inhibited microtubule assembly dependent on microtubule-associated proteins. Limited amounts of homohalichondrin B, the less active agent, were available, so only halichondrin B was studied in detail. Halichondrin B did not interfere with colchicine binding to tubulin, but it was a noncompetitive inhibitor of the binding of vinblastine to tubulin (apparent Ki, 5.0 microM). Halichondrin B was therefore compared with other agents which interfere with the binding of vinca alkaloids to tubulin (vinblastine, maytansine, dolastatin 10, phomopsin A, rhizoxin) in terms of its effects on tubulin polymerization, inhibition of GTP hydrolysis, inhibition of nucleotide exchange, and stabilization of tubulin, as well as the quantitative assessment of its effects on vinca alkaloid binding and inhibition of cell growth. Since halichondrin B was originally isolated from the same organism as the phosphatase inhibitor okadaic acid, and since it is about 50-fold more effective than okadaic acid as an inhibitor of L1210 cell growth, perturbations of cellular microtubules observed following treatment with okadaic acid should be interpreted cautiously.
Bai
R L
RL
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Paull
K D
KD
Herald
C L
CL
Malspeis
L
L
Pettit
G R
GR
Hamel
E
E
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism; D003078:Colchicine / Q000494:pharmacology; D047630:Depsipeptides; D004354:Drug Screening Assays, Antitumor; D004988:Ethers, Cyclic / Q000378:metabolism / Q000494:pharmacology*; D006160:Guanosine Triphosphate / Q000378:metabolism; D006868:Hydrolysis; D007939:Leukemia L1210; D018942:Macrolides; D008453:Maytansine / Q000494:pharmacology; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects; D009842:Oligopeptides / Q000494:pharmacology; D011108:Polymers; D011161:Porifera; D014404:Tubulin / Q000187:drug effects / Q000378:metabolism*; D014747:Vinblastine / Q000378:metabolism; D000095662:Polyether Polyketides
D000970:Antineoplastic Agents; D003078:Colchicine; D047630:Depsipeptides; D004988:Ethers, Cyclic; D006160:Guanosine Triphosphate; D018942:Macrolides; D008453:Maytansine; D009842:Oligopeptides; D011108:Polymers; D014404:Tubulin; D014747:Vinblastine; C070520:homohalichondrin B; C070519:halichondrin B; D000095662:Polyether Polyketides; C064570:dolastatin 10